Evaluation of anticonvulsant activity of angiotensin receptor antagonists in an animal model
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20205534Keywords:
Maximal electroshock, Pentylenetetrazol, Losartan, Telmisartan, Renin angiotensin systemAbstract
Background: Epilepsy is common chronic disorder in clinical practice and there was some studies which shows brain renin angiotensin system may be involved in upregulation of seizures hence present study was planned to investigate whether angiotensin II AT1 receptor antagonists possess anticonvulsant activity in experimental animals.
Methods: The anticonvulsant activity of angiotensin receptor antagonists, losartan (50 mg/kg), telmisartan (30 mg/kg) and candesartan (20 mg/kg), were administered intraperitoneally to the mice and evaluated by using maximum electroshock (MES) and pentylenetetrazol induced seizures (PTZ) seizure methods. The standard was taken as phenytoin for MES and diazepam for PTZ method. Motor impairment of performance was assessed by the inverted screen test and spontaneous motor activity with digital actophotometer.
Results: Losartan demonstrated the anticonvulsant efficacy in MES and PTZ models. Telmisartan and candesartan have anticonvulsant activity in MES induced seizures, but did not show protection against pentylenetetrazol induced seizures. Losartan at dose 50 mg/kg prolonged the mean latency to convulsion (p<0.01) and mean number of convulsions also significantly reduced (p<0.05) convulsions in the mice. Telmisartan and candesartan at dose 30 mg/kg and 20 mg/kg respectively showed significant prolongation in mean latency to convulsion (p<0.05). None of the test drugs i.e. angiotensin receptor antagonists showed significant motor impairment.
Conclusions: Angiotensin receptor antagonists: losartan, telmisartan and candesartan had showed anticonvulsant activity in PTZ and MES seizure methods. The exact mechanism of action of their anticonvulsant action not precisely known and hence there is more studies need to test it in various other animal anticonvulsant models.
References
Srinivas HV. Epilepsy: The future scenario. Ann Indian Acad Neurol. 2010;13:2-5.
Dudra-Jastrzebska M, Andres-Mach MM, Luszczki JJ, Czuczwar SJ. Mood disorders in patients with epilepsy. Pharmacol Rep. 2007;59:369-78.
Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9:68-82.
Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10:446-56.
Fattore C, Perucca E. Novel Medications for Epilepsy. Drugs. 2011;71:2151-78.
Loscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011;20:359-68.
Wright JW, Harding JW. Brain renin-angiotensin--a new look at an old system. Prog Neurobiol. 2011;95:49-67.
Gouveia TL, Frangiotti MI, de Brito JM, de Castro Neto EF, Sakata MM, Febba AC, et al. The levels of renin-angiotensin related components are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy. Neurochem Int. 2012;61:54-62.
Gaitatzis A, Carroll K, Majeed A, W Sander J. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia. 2004;45:1613-22.
Lukawski K, Janowska A, Jakubus T, Czuczwar S. Interactions between angiotensin AT1 receptor antagonists and second-generation antiepileptic drugs in the test of maximal electroshock. Fundam Clin Pharmacol. 2014;28:277-83.
Pereira MG, Becari C, Oliveira JA, Salgado MC, Garcia-Cairasco N, Costa-Neto CM. Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy. Clin Sci (Lond). 2010;119:477-82.
Pelisch N, Hosomi N, Ueno M, Masugata H, Murao K, Hitomi H, et al. Systemic candesartan reduces brain angiotensin II via down regulation of brain renin-angiotensin system. Hypertens Res. 2010;33:161-4.
Coughenour LL, Mclean JR, Parker RB. A new device for the rapid measurement of impaired motor function in mice. Pharmacol Biochem Behav. 1977;6:351-3.
Sankar R, Holmes GL. Mechanisms of action for the commonly used antiepileptic drugs: relevance to antiepileptic drug-associated neurobehavioral adverse effects. J Child Neurol. 2004;19:6-14.
Tchekalarova J, Georgiev VP. Adenosine-angiotensin II interactions in pentylenetetrazol seizure threshold in mice. J Physiol Paris. 1999;93:191-7.
Stragier B, Clinckers R, Meurs A, De Bundel D, Sarre S, Ebinger G, et al. Involvement of the somatostatin-2 receptor in the anti-convulsant effect of angiotensin IV against pilocarpine-induced limbic seizures in rats. J Neurochem. 2006;98:1100-13.
Benicky J, Sanchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology. 2011;36:857-70.
Ferder L, Inserra F, Martínez-Maldonado M. Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr Hypertens Rep. 2006;8:191-8.
